Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic [0.03%]
认知指标作为疾病生物标志物：优化临床前模型与临床上的契合度
Mark Day,Fuat Balci,Hong I Wan et al.
Mark Day et al.
Cognition is a complex set of processes, including attention, learning and memory, that refers to the capacity to encode, consolidate, store and retrieve recent and remotely stored fact (semantic) and experience-based (episodic) memory. The...
Novel analgesic development: from target to patient or patient to target? [0.03%]
从靶点到患者还是从患者到靶点？新的镇痛药研发方向选择
Clifford J Woolf
Clifford J Woolf
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors [0.03%]
阿西替尼，一种新型的抗血管生成药物，在各种实体瘤中具有良好的活性
Toni K Choueiri
Toni K Choueiri
Axitinib is an oral inhibitor of the VEGF, PDGF and colony stimulating factor-1 receptor tyrosine kinases and is currently in development by Pfizer Inc for the potential treatment of various solid tumors. Phase II trials with this agent alo...
SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers [0.03%]
萘吡啶类细胞周期抑制剂和促凋亡刺激剂SNS-595的抗肿瘤作用研究
David A Mills,Houman M Fekrazad,Claire F Verschraegen
David A Mills
Sunesis Pharmaceuticals Inc, under license from Dainippon Sumitomo Pharma Co Ltd, is developing SNS-595, a naphthyridine cell cycle inhibitor and apoptosis stimulator, for the potential treatment of a variety of solid and hematological mali...
AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer [0.03%]
抗X染色体凋亡抑制蛋白的反义寡核苷酸AEG-35156用于治疗癌症的研究药物
Ingo Tamm
Ingo Tamm
Aegera, under license from Idera Pharmaceuticals, is developing AEG-35156, a 19-mer phosphorothioate antisense oligonucleotide targeting the caspase inhibitor X-linked inhibitor of apoptosis protein (XIAP) messenger RNA, for the potential t...
Nicholas Burwick,Aldo M Roccaro,Xavier Leleu et al.
Nicholas Burwick et al.
Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by diffuse bone marrow (BM) infiltration, hepatosplenomegaly, lymphadenopathy, and the presence of a serum IgM monoclonal protein. Clinically, patients may present wit...
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors [0.03%]
小分子抑制剂在RAF/MAP2K/有丝分裂原活化蛋白激酶信号通路中的靶向作用
James A McCubrey,Michele Milella,Agostino Tafuri et al.
James A McCubrey et al.
Mutations occur in some cancer cells and result in elevated expression or constitutive activation of various growth factor receptors. The Raf/MEK/ERK pathway is often activated by mutations in these growth factor receptors. This pathway is ...
Guofeng Ye,Rakesh Tiwari,Keykavous Parang
Guofeng Ye
The majority of marketed drugs or drug candidates that target protein kinases and which are currently undergoing clinical trials are ATP binding site inhibitors. The process of designing a selective inhibitor as an ATP mimic is challenging,...
Gagan Deep,Rajesh Agarwal
Gagan Deep
Cancer cells have deregulated cell-cycle progression with overexpression of positive regulators and inhibition of negative regulators, giving them unlimited replication potential. Therefore, development of agents targeting the deregulated c...
Muller Fabbri
Muller Fabbri
The term epigenetics refers to all heritable changes in gene expression that are not associated with concomitant alterations in the DNA sequence. Reversible DNA methylation and histone modifications are the hallmarks of epigenetic gene regu...